Form D · Biotechnology
Co-Diagnostics, Inc.
Salt Lake City, UT · CIK 0001692415
Offering snapshot reported Jan 14, 2022 · SEC filing
- Reported sold
- $46.6M Offering amount: $47.2M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 31, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 14, 2022 | Initial | $46,559,793 | No comparison | 22 | SEC filing |
| Dec 29, 2016 | Initial | $750,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-429617
Source: Form D, filed Jan 14, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Reed L. Benson | Director, Executive |
| Brian Brown | Executive |
| Dwight Egan | Executive |
| Brent Satterfield | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2401 South Foothill Drive Suite D
Salt Lake City, UT, 84109
Salt Lake City, UT, 84109